Lv51
966 积分 2023-02-09 加入
The landscape of objective response rate of anti-PD-1/L1 monotherapy across 31 types of cancer: a system review and novel biomarker investigating
3小时前
已完结
FDA Approval Summary: Pembrolizumab for the Treatment of Tumor Mutational Burden–High Solid Tumors
3小时前
已完结
Association between cancer genes and germ layer specificity
3小时前
已完结
Immunotherapy for ovarian cancer: towards a tailored immunophenotype-based approach
2天前
已完结
CAR T Cells and T-Cell Therapies for Cancer
3天前
已完结
CAR-T therapy in solid tumors
3天前
已完结
CAR T therapy beyond cancer: the evolution of a living drug
3天前
已完结
Novel strategies to manage CAR-T cell toxicity
3天前
已完结
Tumour-associated vasculature in T cell homing and immunity: opportunities for cancer therapy
3天前
已完结
Noncanonical and mortality-defining toxicities of CAR T cell therapy
3天前
已完结
皖公网安备34019202002308
